Jobert M, Wilson FJ, Ruigt GS, Brunovsky M, Prichep LS, Drinkenburg WH et al (2012) Guidelines for the recording and evaluation of pharmaco-EEG data in man: the International Pharmaco-EEG Society (IPEG). Neuropsychobiology 66(4):201–220

Article  PubMed  Google Scholar 

Hashimoto Y, Sheiner LB (1991) Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis. J Pharmacokinet Biopharm 19(3):333–353

Article  CAS  PubMed  Google Scholar 

Bruhn J, Bouillon TW, Shafer SL (2000) Bispectral index (BIS) and burst suppression: revealing a part of the BIS algorithm. J Clin Monit Comput 16(8):593–596

Article  CAS  PubMed  Google Scholar 

Drugs UNOo, Laboratory C, Section S, Group ENoFSIDW (2009). Guidelines on Representative Drug Sampling: UN;

Girdwood ST, Kaplan J, Vinks AA (2021) Methodologic progress note: opportunistic sampling for pharmacology studies in hospitalized children. J Hosp Med 16(1):35

Article  PubMed  PubMed Central  Google Scholar 

Pronzato L (2010) Penalized optimal designs for dose-finding. J Stat Plann Inference 140(1):283–296

Article  Google Scholar 

Jackson C, Ou Y-C, Chao T-Y, En M, Hung NA, Wang D et al An open-label, pharmacokinetic study to determine the bioavailability, safety and tolerability of single dose oral docetaxel (Oradoxel) in metastatic prostate cancer (mPC) patients treated with IV docetaxel

Malingré MM, Richel DJ, Beijnen JH, Rosing H, Koopman FJ, Ten Bokkel Huinink WW et al (2001) Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol 19(4):1160–1166

Article  PubMed  Google Scholar 

Kim TE, Gu N, Yoon SH, Cho JY, Park KM, Shin SG et al (2012) Tolerability and pharmacokinetics of a new P-glycoprotein inhibitor, HM30181, in healthy korean male volunteers: single- and multiple-dose randomized, placebo-controlled studies. Clin Ther 34(2):482–494

Article  CAS  PubMed  Google Scholar 

Bruno R, Vivier N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB (1996) A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 24(2):153–172

Article  CAS  PubMed  Google Scholar 

Duffull S, Waterhouse T, Eccleston J (2005) Some considerations on the design of population pharmacokinetic studies. J Pharmacokinet Pharmacodyn 32(3–4):441–457

Article  PubMed  Google Scholar 

Duffull SB, Hooker AC (2017) Assessing robustness of designs for random effects parameters for nonlinear mixed-effects models. J Pharmacokinet Pharmacodyn 44:611–616

Article  PubMed  Google Scholar 

Johnson JR (2018) Methods for handling concentration values below the limit of quantification in PK studies. PhUSE US Connect 2018:1–9

Google Scholar